Capricor Therapeutics, Inc.
CAPR
$7.20
$0.3054.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M |
| Cost of Revenue | 14.55M | 11.81M | 12.50M | 11.10M | 9.94M |
| Gross Profit | -3.42M | -9.55M | -8.53M | -6.19M | 2.15M |
| SG&A Expenses | 4.27M | 3.46M | 3.06M | 4.07M | 3.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.83M | 15.27M | 15.56M | 15.17M | 13.37M |
| Operating Income | -7.70M | -13.01M | -11.59M | -10.27M | -1.28M |
| Income Before Tax | -7.12M | -12.56M | -11.00M | -9.79M | -762.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.12M | -12.56M | -11.00M | -9.79M | -762.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.12M | -12.56M | -11.00M | -9.79M | -762.10K |
| EBIT | -7.70M | -13.01M | -11.59M | -10.27M | -1.28M |
| EBITDA | -7.32M | -12.65M | -11.23M | -9.93M | -973.70K |
| EPS Basic | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 |
| Normalized Basic EPS | -0.10 | -0.24 | -0.22 | -0.20 | -0.02 |
| EPS Diluted | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 |
| Normalized Diluted EPS | -0.10 | -0.24 | -0.22 | -0.20 | -0.02 |
| Average Basic Shares Outstanding | 44.51M | 33.09M | 31.84M | 31.35M | 30.66M |
| Average Diluted Shares Outstanding | 44.51M | 33.09M | 31.84M | 31.35M | 30.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |